Dr Vladimir Zelenko Says His Cancer Has Spread, Is Exploring Experimental, Alternative Treatment Options

-
Dr. Zev Zelenko, who gained national attention for his “Zelenko Protocol” to treat Covid-19 infections at the height of the Covid-19 pandemic, says he has suffered a significant setback in his fight again cancer.

We are so sorry to have to post this update from Zelenko Freedom Foundation: "It is with immense sorrow that we announce the passing of our founder Dr. Vladimir “Zev” Zelenko."

“Unfortunately, my cancer has progressed and spread to my remaining lung, and may have also spread to my left hip, and low[er] back. I will have biopsies of the hip and back soon,” he said.


“There are experimental and alternative treatment options that I am exploring. I feel good and have no fear. I may have to scale down some of my smaller media events but fully intend to stay in the fight as long as I have consciousness.”

“It has been four years since I was supposed to die. Every day since has been miraculous and I attribute my continuous survival to the prayers of loving people,” he said.

“My Hebrew name is Velvel Wolf Zev Ben Leah.”

“It really isn’t important when and how a person dies. It is much more important how a person lives.

Source: https://www.theyeshivaworld.com/news/headlines-breaking-stories/2075007/dr-zelenko-says-his-cancer-has-spread-is-exploring-experimental-alternative-treatment-options.html

Update: 

Comments

  1. TereseJune 29, 2022 at 7:04 PM

    Wow, that is a beautiful quote!! Thank you! And thank you for a well lived life and for your courage in the midst of adversity. God bless you! You are in my prayers.

    ReplyDelete

Post a Comment

Labels

Show more

Archive

Show more

Popular posts from this blog

GLP-1 Muscle Loss: How to Preserve Lean Mass, Strength & Metabolic Health

-
Image
GLP-1-based medications have changed the treatment of obesity by making substantial, sustained weight loss possible for many people. But as these medicines become more widely used, another question has become increasingly important: How much of the weight lost on a GLP-1 drug comes from muscle or other lean tissue—and can that loss be minimized? The evidence shows a nuanced answer. People taking semaglutide, tirzepatide and related incretin-based medicines generally lose much more fat than lean tissue . At the same time, absolute lean mass usually falls during substantial weight loss. Importantly, lean mass is not the same thing as skeletal muscle : DXA-based “lean mass” also includes water, organs and other non-fat tissues. Therefore, a finding that lean mass decreased does not automatically mean that the same amount of skeletal muscle was lost. Recent 2026 meta-analyses suggest that roughly one-quarter to one-third of total weight lost with incretin therapy may be classified as lean ...
Read more

GLP-1 2.0 and Pipeline: The Next Generation of Obesity Drugs

-
Image
By Dr. Frank Yap, MD  · One Day Media Network · Last Updated October 2026 Quick Answer "GLP-1 2.0" is the second wave of obesity medicines built on semaglutide and tirzepatide. It improves on the first wave in five ways: more potency (retatrutide, a triple agonist, averaged 28.3% weight loss at 80 weeks in Lilly's TRIUMPH-1 trial), new mechanisms (amylin and glucagon), easier formats (daily pills already approved; monthly injections in Phase 3), better body composition , and lower prices . As of September 29, 2026, no next-generation injectable is approved yet : retatrutide's FDA filing is planned for Q1 2027 and CagriSema's FDA decision is expected in late 2026. Approved 2.0-era products today are the oral drugs (Wegovy pill, Foundayo) and high-dose Wegovy HD. Disclosure: This article is educational and is not medical advice. ...
Read more

Semaglutide vs Tirzepatide vs Retatrutide: Best Weight Loss Peptides in 2026

-
Image
Medically Reviewed by: Dr. Frank Yap, MD | Written by: OneDayMD Editorial Team | Published: March 2026 | Last updated: October 2026 Quick Answer Semaglutide (“sema”), tirzepatide (“tirz”), and retatrutide (“reta”) represent three stages in the evolution of incretin-based weight-loss medications: a single GLP-1 receptor agonist, a dual GIP/GLP-1 receptor agonist, and an investigational triple GIP/GLP-1/glucagon receptor agonist, respectively. Semaglutide is an FDA-approved GLP-1 receptor agonist that has demonstrated average weight loss of approximately 15% in clinical trials, with some individuals losing more. Tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated average weight loss of up to approximately 21–22% in trials. Retatrutide, an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors, has shown promising weight-loss results in clinical trials but is not yet FDA-approved. What changed in this update (Oct 2026): replaced pre-Phase-3 esti...
Read more

Dr William Makis Ivermectin Protocol 2026 – Complete Guide + Patient Outcomes

-
Image
Medically Reviewed by: Dr Frank Yap, MD | Written and Compiled by:     OneDayMD Editorial Team | Last Updated:  October  2026 Dr. William Makis MD (McGill Medicine, 110+ peer-reviewed publications) has treated a large volume of cancer patients using repurposed drugs since 2023 and has documented outcomes publicly on Substack and X. This continuously updated 2026 guide compiles Dr. Makis's latest protocols (from his Substack, X posts through 2026, and direct patient correspondence). We cross-reference his exact dosages, schedules, combinations, safety data, sourcing, and real patient outcomes (anonymized but verifiable on his channels). Important Disclaimer: This content is for educational purposes only and does not constitute medical advice. Ivermectin is used off-label for cancer treatment. Always consult with a knowledgeable physician whom you trust to manage your health. Individual results may vary. Do not self-medicate with ivermectin without proper bloodwork ...
Read more

GLP-1 Hub: Approved Drugs, Pills vs Injections, Retatrutide & Side Effects

-
Image
Home › GLP-1 Hub By Dr. Frank Yap, MD | One Day Media Network | Published October 13, 2026 | Last updated: October 13, 2026 | Purpose: evidence and safety education, not individual medical advice Quick Answer As of October 2026, the FDA has approved two GLP-1 weight-loss pills, oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron, April 1, 2026), alongside weekly injections such as Wegovy, Zepbound, Ozempic and Mounjaro. Retatrutide and CagriSema are not approved in the US. Compounded and gray-market GLP-1 products are not FDA-approved. Use a licensed prescriber and a regulated pharmacy. On this page Which GLP-1 medicines are approved in October 2026? Are GLP-1 pills as effective as injections? Retatrutide and CagriSema: what is known so far? Safety and side...
Read more

Top Smart Glasses for the Visually Impaired (2026): eSight, Envision, OrCam & More

-
Image
Medically & Technically Reviewed by: OneDayMD Editorial Team | Originally Published: August 9, 2026 | Updated: October 2026 Quick Answer There is no single "best" smart glasses for visual impairment in 2026 — the right pick depends on how much usable vision remains. For low vision (residual central vision from macular degeneration, diabetic retinopathy, or Stargardt disease), medical-grade enhancers like eSight Go ($4,950) or Acesight VR digitally magnify and boost contrast. For blind or near-blind users, AI-interpretation glasses like Envision Glasses ($2,499), Ally Solos (from $399), or a clip-on OrCam MyEye 3 Pro (remaining dealer stock, $3,689–$4,490) read text and describe scenes aloud. The cheapest mainstream option is Meta's expanding AI-glasses lineup — Ray-Ban Meta, Meta Glasses (Adventurer/Fury), and Meta Glasses by Kylie — starting at $299, which isn't purpose-built for accessibility but has become a popular everyday alternative thanks to ...
Read more

Fenbendazole Joe Tippens Protocol: A Step-by-Step Guide (2026)

-
Image
Medically Reviewed by: Dr Frank Yap, MD | Written by:     OneDayMD Editorial Team | Last Updated:   September  2026 If you have been diagnosed with cancer, or have a loved one that is suffering from cancer, chances are you have heard about the Joe Tippens Cancer Protocol. The Fenbendazole Cancer Protocol has been gaining rapid interest over the past years following some fenbendazole advanced cancer success stories  (800+ case reports) and a 2026 publication, " Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients : Results from a Prospective Observational Cohort of 197 patients." We have seen tremendous demand for some sort of guide on how to use fenbendazole for cancer as there is also tremendous confusion both from the healthcare and non-healthcare communities. Joe Tippens founded the protocol (1) after he was told a story about a ...
Read more

How to Get Ivermectin in the US: Pharmacies, Legal Status & State-by-State Access (2026)

-
Image
Medically Reviewed by: OneDayMD Editorial Team | Last Updated: August 2026 An updated, evidence-based guide to ivermectin's federal and state legal status, how to obtain a prescription, which states allow pharmacist-dispensed or OTC access, and a directory of pharmacies that fill ivermectin prescriptions in the US. Quick Answer (AI & Search Summary) Ivermectin is still classified federally as a prescription-only drug for human use. It has not been reclassified as OTC by the FDA. However, five states — Arkansas, Idaho, Louisiana, Tennessee, and Texas — have passed laws letting pharmacists dispense it without a doctor's prescription, and roughly half a dozen more have active bills. Everywhere else, you need a prescription from a doctor, urgent care provider, or telehealth service. Individual pharmacists retain the right to decline to dispense or stock it even where state law allows it. Table of Contents Current Legal Status (Federal & State) State-by-...
Read more

DMSO 101: Benefits, Uses, Dosage and Side Effects (2026)

-
Image
Quick Summary: DMSO (Dimethyl Sulfoxide) is a naturally occurring compound with decades of research behind its use as an anti-inflammatory, analgesic, and cellular-protective agent. FDA-approved for interstitial cystitis, it has been used off-label by athletes, physicians, and patients for musculoskeletal injuries, chronic pain, wound healing, and more. This guide covers what DMSO is, how it works, the evidence for its key uses, safety considerations, dosing guidance, and where to find practitioners who use it. All off-label uses are experimental. Consult a qualified healthcare provider before use. A Patient Story: From Lung Transplant List to Clear CT Scans In 2022, Erica Eyres, a vigorous fifty-six-year-old aerobics instructor who had struggled to breathe, was given “absolutely devastating” news: She might need a lung transplant. She had never smoked, ran cross-country track in high school, and was a personal trainer for years, but, by 2024, a transplant assessment was arranged. “I d...
Read more

Ivermectin, Fenbendazole and Mebendazole: A Peer-Reviewed Protocol for Cancer Treatment (2026 Update)

-
Image
Medically Reviewed by: OneDayMD Editorial Team | Last Updated: April 2026 In September 2024, a first-of-its-kind protocol utilizing ivermectin, fenbendazole, and mebendazole for cancer treatment was peer-reviewed and officially published in the Journal of Orthomolecular Medicine . Led by researchers Dr. Ilyes Baghli, Dr. Pierrick Martinez, and FLCCC's Dr. Paul Marik, the protocol applies antiparasitic drugs — originally developed to combat parasites — to cancer treatment, building on emerging preclinical and clinical evidence of their anticancer properties. This trio of repurposed drugs has been shown to disrupt the growth of cancer cells, particularly by targeting microtubules, the essential structures that allow cancer to multiply uncontrollably. What makes this protocol even more potent is the synergistic effect when these drugs are used together, creating a powerful new affordable weapon against cancer. Journal of Orthomolecular Medicine 2024 Targeting the Mitochondrial-Stem C...
Read more